Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542738 | 0.90 | ALDH1A1 (0.39) | ALDH1A1TAAR1L3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL17898217 | 0.83 | KCNH2 (0.57) | ALDH1A1POLBRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL3410050 | 0.82 | PNMT (0.43) | TAAR1HTR2BCYP3A4KDM4CKDM5B | |
| SCHEMBL7674816 | 0.81 | HTR2C (0.38) | HTR2BRAB9ASMN1; SMN2CYP19A1 | |
| SCHEMBL7669156 | 0.80 | YTHDC1 (0.41) | TAAR1 | |
| SCHEMBL17537258 | 0.80 | NR4A2 (0.42) | ALDH1A1POLBKDM5AKDM2BKDM4C | |
| SCHEMBL5258991 | 0.79 | FFAR1 (0.36) | ALDH1A1PKMGBA1CYP1A2CYP3A4 | |
| SCHEMBL415697 | 0.78 | CHRM4 (0.44) | ALDH1A1CALM1BRD4TAAR1L3MBTL1 | |
| SCHEMBL7675792 | 0.78 | CYP19A1 (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C19CYP19A1 | |
| SCHEMBL7672911 | 0.78 | MBOAT4 (0.44) | TAAR1KDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-111699189-B | Modulators of beta-3 adrenergic receptors useful for treating or preventing heart failure and disorders associated therewith | 艾尼纳制药公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119095979-A | Target enrichment | 新英格兰生物实验室公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4103652-A1 | FLUORESCENT RHODAMINE DYES WITH ENHANCED CELL PERMEABILITY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| CN-101370792-A | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC (US) | 2009-02-18 | — | — | CN | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | CELLTECH THERAPEUTICS LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
| EP-1133488-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031067-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| WO-1994026715-A1 | AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | ALDH1A1 700/4885CALM1 690/4885BRD4 3894/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885CALM1 3410/4885BRD4 142/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885CALM1 3410/4885BRD4 142/4885 |
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | ITGA1, ITGB1, VCAM1 | ALDH1A1 961/4885CALM1 1045/4885BRD4 1544/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ALDH1A1 3541/4885CALM1 3027/4885BRD4 1/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | ALDH1A1 3250/4885CALM1 3091/4885BRD4 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.